MetaCap

Palvella Therapeutics Inc. (PVLA)

NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

142.85-2.92 (-2.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PVLA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.53
52-week range
72.23 – 179.95
Day range
142.22 – 148.69
Volume / Avg
192.67K / 240.41K
Beta
—

52-week range

$72.23$179.95

PVLA stock today

Palvella Therapeutics (PVLA) closed at $142.85 on Nov 20, down 2.00% (-$2.92), versus the S&P 500's 3.70% decline. Shares are 20.6% below their 52-week high of $179.95, set on Nov 9, 2026 and 97.8% above the 52-week low of $72.23, in the middle of the past year's range. PVLA is up 36.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.8%.

Palvella Therapeutics has posted a net loss over the last twelve months (EPS of -$5.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Palvella Therapeutics

Company profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Wesley H. Kaupinen
Headquarters
Wayne, PA
Employees
29

Financial highlights

Full financials

Palvella Therapeutics reported a net loss of $41.7 million, compared with a loss of $17.4 million a year earlier. Diluted earnings per share came in at -$3.71.

Palvella Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$42.81M$25.90M$31.42M
Growth——+65.28%-17.56%+7.14%
Net income$-41.72M$-17.43M$18.69M$-33.28M$-45.74M
EPS (diluted)$-3.71$-7.83$2.17—$-0.71

Analyst forecast

Forecast

Consensus (17 analysts)

strong_buy

Avg. price target

$233.44+63.42%

  • Strong buy 0
  • Buy 17
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $207.00High $267.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.70 vs $-1.65
Surprise
-3.03%

PVLA news

All PVLA news

Palvella Therapeutics peers

Health Care sector
PVLA peer companies
CompanyPrice% ChgMarket capCompare
LKFTLakefront Biotherapeutics ADR33.31-0.24%$2.18Bvs PVLA
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs PVLA
NAMSNewAmsterdam Pharma Company N.V.18.41-5.64%$2.21Bvs PVLA
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs PVLA
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs PVLA
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs PVLA
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs PVLA
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs PVLA

Indexes, lists and sector

Palvella Therapeutics stock FAQ

What is Palvella Therapeutics's stock price today?

PVLA last traded at $142.85 as of Nov 20, 4:00 PM EST, down 2.00% on the day. Prices are delayed at least 15 minutes.

Does Palvella Therapeutics pay a dividend?

No. Palvella Therapeutics does not currently pay a regular cash dividend.

Who is Palvella Therapeutics's CEO?

Mr. Wesley H. Kaupinen is the chief executive officer of Palvella Therapeutics Inc., which has about 29 employees.

Has PVLA ever split its stock?

Yes. The most recent PVLA stock split was a 1-for-80 split on Apr 23, 2024.

What is the PVLA 52-week high?

The 52-week high for PVLA is $179.95 and the 52-week low is $72.23. The stock is currently 20.6% below its high.

Compare PVLA